Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells

被引:104
作者
Buac, Daniela
Schmitt, Sara
Ventro, George
Kona, Fathima Rani
Dou, Q. Ping [1 ,2 ,3 ,4 ]
机构
[1] Wayne State Univ Sch Med, Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA
[2] Wayne State Univ Sch Med, Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA
[3] Wayne State Univ Sch Med, Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA
[4] Wayne State Univ Sch Med, Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA
关键词
Cancer therapy; Ubiquitin-Proteasome System; Apoptosis; Metal Complexes; Disulfiram; Antabuse; Proteasome inhibitors; UPS inhibitors; FACTOR-KAPPA-B; BREAST-CANCER; PYRROLIDINE DITHIOCARBAMATE; PROSTATE-CANCER; PROTEIN-DEGRADATION; ANTIALCOHOLISM DRUG; PLATINUM COMPLEXES; APOPTOSIS INDUCERS; ANTITUMOR-ACTIVITY; MAMMALIAN-CELLS;
D O I
10.2174/138955712802762040
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dithiocarbamates are a class of metal-chelating compounds with various applications in medicine. They have been used for the treatment of bacterial and fungal infections, possible treatment of AIDS, and most recently cancer. Their anti-tumor effects can in part be attributed to their ability to complex tumor cellular copper, leading to binding to and inhibition of the proteasome and in turn initiating tumor cell-specific apoptosis. Current chemotherapeutic agents are highly toxic and therefore their efficacy in the eradication of tumors is greatly limited. As a result many scientists have joined the quest for novel targeted therapies in hopes of reducing toxicity while maximizing potency and proteasome inhibition has become an attractive therapy in this regard. Here we discuss the origins, mechanism, and evolution of dithiocarbamates as potent proteasome inhibitors and therefore anti-cancer agents.
引用
收藏
页码:1193 / 1201
页数:9
相关论文
共 103 条
[1]   The proteasome: structure, function, and role in the cell [J].
Adams, J .
CANCER TREATMENT REVIEWS, 2003, 29 :3-9
[2]   The proteasome: a novel target for cancer chemotherapy [J].
Almond, JB ;
Cohen, GM .
LEUKEMIA, 2002, 16 (04) :433-443
[3]   Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts [J].
An, B ;
Goldfarb, RH ;
Siman, R ;
Dou, QP .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (12) :1062-1075
[4]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[5]   HTLV-1 tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells [J].
Arima, N ;
Arimura, K ;
Tokito, Y ;
Sakaki, Y ;
Matsushita, K ;
Orihara, K ;
Akimoto, M ;
Ozaki, A ;
Kukita, T ;
Hagiwara, T ;
Hamada, H ;
Tei, C .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (02) :195-201
[6]   IDENTITY OF THE 19S PROSOME PARTICLE WITH THE LARGE MULTIFUNCTIONAL PROTEASE COMPLEX OF MAMMALIAN-CELLS (THE PROTEASOME) [J].
ARRIGO, AP ;
TANAKA, K ;
GOLDBERG, AL ;
WELCH, WJ .
NATURE, 1988, 331 (6152) :192-194
[7]  
BODENNER DL, 1986, CANCER RES, V46, P2745
[8]  
BODENNER DL, 1986, CANCER RES, V46, P2751
[9]   Exploring the Structural Requirements for Inhibition of the Ubiquitin E3 Ligase Breast Cancer Associated Protein 2 (BCA2) as a Treatment for Breast Cancer [J].
Brahemi, Ghali ;
Kona, Fathima R. ;
Fiasella, Annalisa ;
Buac, Daniela ;
Soukupova, Jitka ;
Brancale, Andrea ;
Burger, Angelika M. ;
Westwell, Andrew D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2757-2765
[10]  
Brar SS, 2004, MOL CANCER THER, V3, P1049